Calendario›VTRS›Selatogrel

Selatogrel

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome

Ensayo de Viatris Inc en Chronic Coronary Syndrome (del registro, en inglés).

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

20

previstos

Centros

1

Fin del objetivo primario

oct 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jun 2026.

Qué mide

Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) (Up to 36 hours post-dose) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of this study is to evaluate the pharmacokinetics (PK), pharmacodynamics, and tolerability of a single dose of selatogrel in Chinese adults with chronic coronary syndrome. Pharmacokinetics is the study of the absorption and breakdown of the study drug in the body. Pharmacodynamics is the study of the effect of the study drug on the body. Researchers will compare selatogrel to a placebo (a look-alike substance that contains no drug). Participants will stay at the research clinic for 3 or 4 days (2 or 3 nights), during which time they will receive a single dose of selatogrel or placebo. A telephone call for post-trial safety follow-up will be done 30-40 days after the participant leaves the clinic.

Más ensayos de VTRS

Todos los de VTRS, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07615868), actualizada en jul 2026.